Otsuka Pharmaceutical Co Ltd v. Zenara Pharma Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Defendant: Zenara Pharma Private Limited (India)
  • Plaintiff’s Counsel: Morris, Nichols, Arsht & Tunnell LLP; Venable LLP
• Case Identification: 1:26-cv-00181, D. Del., 02/19/2026
• Venue Allegations: Plaintiff alleges venue is proper because Defendant is a foreign corporation incorporated in India and may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market generic tolvaptan tablets constitutes an act of infringement of three patents related to the drug's manufacturing process and formulation.
• Technical Context: The dispute centers on tolvaptan, marketed by Plaintiff as JYNARQUE®, a prescription drug used to treat adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).
• Key Procedural History: The action was triggered by Defendant’s submission of ANDA No. 220377 with a Paragraph IV certification, alleging non-infringement or invalidity of Plaintiff's patents. Plaintiff states it commenced this action within the 45-day statutory window following receipt of Defendant's notice letter, which preserves a potential 30-month stay of FDA approval for the generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,501,730 - "Process for Preparing Benzazepine Compounds or Salts Thereof"

• Patent Identification: U.S. Patent No. 8,501,730, "Process for Preparing Benzazepine Compounds or Salts Thereof," issued August 6, 2013 (the ’730 Patent).

The Invention Explained

• Problem Addressed: The patent's background describes prior art methods for synthesizing certain benzazepine compounds (the chemical class of tolvaptan) as unsuitable for industrial-scale production due to low yield and purity ʼ730 Patent, col. 2:48-59
• The Patented Solution: The invention is a specific chemical process for creating the final active pharmaceutical ingredient. It claims the product (the benzazepine compound) that results from a specific reduction reaction. This reaction converts a precursor ketone (a benzazepin-5-one) into the desired alcohol (a 5-hydroxy-benzazepine) using a specific, limited quantity (0.25 to 1.0 mole equivalent) of a hydrogenating agent like sodium borohydride ʼ730 Patent, claim 1 This controlled process is described as producing the desired compound in high yield and purity by avoiding undesirable side reactions, such as dehalogenation, that can occur with other methods ʼ730 Patent, col. 13:3-8
• Technical Importance: The process provides a method for large-scale manufacturing of a pharmaceutically important compound with high purity, which is a critical requirement for regulatory approval and commercial viability.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶37
• Essential elements of claim 1 include:
  • A highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methyl-benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine, or a salt thereof.
  • Which is produced by the process of reducing a precursor benzazepin-5-one compound.
  • The reduction is performed in the presence of a hydrogenating agent selected from a specific group (lithium aluminum hydride, sodium borohydride, zinc borohydride, and diborane).
  • The hydrogenating agent is used in an amount of 0.25 to 1 mole per 1 mole of the precursor compound.

U.S. Patent No. 10,905,694 - "Pharmaceutical Solid Preparation Comprising Benzazepines and Production Method Thereof"

• Patent Identification: U.S. Patent No. 10,905,694, "Pharmaceutical Solid Preparation Comprising Benzazepines and Production Method Thereof," issued February 2, 2021 (the ’694 Patent).

The Invention Explained

• Problem Addressed: The patent background explains a two-fold technical challenge. First, the active ingredient (tolvaptan) has poor solubility, hindering its absorption in the body. Second, a prior solution that improved solubility by creating an amorphous composite of the drug with hydroxypropylcellulose resulted in tablets that failed to disintegrate properly in the gastrointestinal tract, rendering the drug ineffective ʼ694 Patent, col. 2:32-49
• The Patented Solution: The invention is a specific pharmaceutical formulation, claimed as a product-by-process. The solution involves a multi-step process: (1) creating granules from an amorphous composite of tolvaptan and hydroxypropylcellulose, mixed with other excipients like crystalline cellulose; and (2) mixing these granules with a specific disintegrant—low substituted hydroxypropylcellulose (L-HPC) possessing a tightly defined average particle diameter (45 to 65 µm) and 90% cumulative particle diameter (150 to 200 µm) ’694 Patent, claim 1 ’694 Patent, col. 2:59-65 This specific combination is described as achieving both excellent solubility and superior disintegration properties.
• Technical Importance: The invention provides a formulation that allows a poorly soluble drug to be delivered effectively in a solid oral dosage form (a tablet), overcoming a significant hurdle in pharmaceutical development.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶47
• Essential elements of claim 1 include:
  • A pharmaceutical solid preparation obtained by a method comprising multiple steps.
  • Step 1: producing amorphous composites of the active ingredient and hydroxypropylcellulose.
  • Step A: processing a mixture of the amorphous composites, crystalline cellulose, and corn starch/lactose into granules.
  • Step 2: mixing the granules from Step A with low substituted hydroxypropylcellulose (L-HPC).
  • The L-HPC must have an average particle diameter of 45 to 65 µm and a 90% cumulative particle diameter of 150 to 200 µm.
  • Step 3: processing the final mixture into a solid preparation.

U.S. Patent No. 8,273,735 - "Process for Preparing Benzazepine Compounds or Salts Thereof"

• Patent Identification: U.S. Patent No. 8,273,735, "Process for Preparing Benzazepine Compounds or Salts Thereof," issued September 25, 2012 (the ’735 Patent).
• Technology Synopsis: The patent addresses the need for an industrial-scale process to produce benzazepine compounds, like tolvaptan, in high yield and purity ’735 Patent, abstract It claims a process for preparing a key chemical intermediate—a specific benzoic acid compound—which is then used in the synthesis of the final active drug ʼ735 Patent, col. 3:25-42
• Asserted Claims: Claims 6-8 and 10 are asserted Compl. ¶56
• Accused Features: The complaint seeks a declaratory judgment that Zenara's ANDA products are or will be made by a process patented by the ’735 Patent, and that their importation into the U.S. would constitute infringement under 35 U.S.C. § 271(g) Compl. ¶¶54, 56, 58

III. The Accused Instrumentality

Product Identification

• Defendant Zenara's tolvaptan tablets in 15, 30, 45, 60, and 90 mg dosage strengths, for which Zenara has submitted ANDA No. 220377 to the FDA Compl. ¶2

Functionality and Market Context

• The products are prescription drugs intended as generic versions of Otsuka’s JYNARQUE® tablets Compl. ¶28 The complaint alleges they are intended to be pharmaceutically and therapeutically equivalent to JYNARQUE®, which is used to slow kidney function decline in adults with autosomal dominant polycystic kidney disease Compl. ¶15 Compl. ¶35 The filing of the ANDA itself signifies Zenara’s intent to commercially manufacture, use, and sell these products in the United States upon receiving FDA approval Compl. ¶28

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not provide sufficient detail for a claim-chart analysis. It makes general allegations of infringement under 35 U.S.C. § 271(e)(2)(A) based on the act of submitting the ANDA, and for declaratory judgment of future infringement if the ANDA is approved (Compl. ¶¶37, 47, 56). The specific details of Zenara's manufacturing process and formulation are contained within its confidential ANDA and are not detailed in the complaint.

• Identified Points of Contention:
  • Process Identity (for the '730 and '735 Patents): A central dispute will concern whether the confidential process Zenara uses to manufacture its tolvaptan active pharmaceutical ingredient (API) is the same as, or equivalent to, the processes claimed in the ’730 and ’735 Patents. This raises the evidentiary question of what Otsuka can prove through discovery regarding Zenara's specific chemical reagents, reaction conditions, and intermediate synthesis steps.
  • Formulation Identity (for the '694 Patent): For the formulation patent, a key question will be whether Zenara’s tablet formulation and manufacturing process fall within the scope of the product-by-process claims. Specifically, the analysis may focus on whether the disintegrant used by Zenara is "low substituted hydroxypropylcellulose" and, if so, whether it meets the precise particle size distribution limitations recited in claim 1.
  • Product-by-Process Claim Scope: The case may raise legal questions regarding the scope of the asserted product-by-process claims. A court will need to determine whether infringement requires practicing the claimed process steps, or if producing a product that is materially identical to that produced by the claimed process is sufficient, a point of ongoing debate in patent law.

V. Key Claim Terms for Construction

’730 Patent

• The Term: "reducing...in the presence of a hydrogenating agent...in an amount of 0.25 to 1 mole per 1 mole of the compound (1)" (from claim 1).
• Context and Importance: This term defines the core process step. The infringement analysis for this product-by-process claim will depend entirely on whether Zenara’s manufacturing process uses a specified reducing agent within this exact molar ratio. Practitioners may focus on this term because it appears to be the primary point of novelty over prior art methods.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim recites a group of four different hydrogenating agents, which may suggest the invention is not limited to a single specific reagent ʼ730 Patent, claim 1
  • Evidence for a Narrower Interpretation: The specification explicitly warns against using amounts of the hydrogenating agent outside the claimed range, stating that excess agent can lead to an "undesirable dehalogenating reaction" ʼ730 Patent, col. 13:3-8 This stated technical reason for the upper bound of "1 mole" could support a narrow construction where the claimed range is a critical limitation.

’694 Patent

• The Term: "low substituted hydroxypropylcellulose, [which]...has an average particle diameter of 45 to 65 µm, and has a 90% cumulative particle diameter of 150 to 200 µm" (from claim 1).
• Context and Importance: This term defines the physical characteristics of the required disintegrant. Whether Zenara's generic product infringes may depend on whether the excipient it uses meets these precise numerical ranges.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The complaint does not provide sufficient detail for analysis of this element.
  • Evidence for a Narrower Interpretation: The specification provides experimental data comparing tablets made with L-HPC inside the claimed particle size range to those made with L-HPC outside the range (specifically, "LH-31," which has a smaller particle diameter) ʼ694 Patent, col. 19:35-41 '694 Patent, Table 1 The data shows that the L-HPC with smaller particles resulted in significantly longer disintegration times, suggesting the claimed ranges are not arbitrary but are essential to the invention's function and may be strictly construed.

VI. Other Allegations

• Indirect Infringement: The complaint makes conclusory allegations of future active inducement and contributory infringement under 35 U.S.C. § 271(b) and (c) should the ANDA be approved Compl. ¶39 Compl. ¶49 No specific facts, such as instructions in a product label, are alleged to support these claims.
• Willful Infringement: The complaint does not plead willfulness as a separate count. However, it alleges that Zenara has "actual knowledge" of the patents-in-suit, which could form the basis for a later claim of willfulness Compl. ¶36 Compl. ¶46 Compl. ¶57 This knowledge is premised on Zenara's Paragraph IV certification and notice letter.

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to the following questions, which can only be determined after discovery into Zenara's confidential ANDA submission.

• A core issue will be one of process identity: Can Otsuka prove that Zenara's confidential manufacturing processes for its API and final drug product replicate the specific steps, reagents, quantities, and excipient characteristics required by the asserted product-by-process claims of the '730, '735, and '694 patents?
• A key evidentiary question will be one of physical characterization: Does the disintegrant used in Zenara's formulation, as described in its ANDA, possess the exact particle size distribution metrics recited in claim 1 of the ’694 patent, or does it fall outside this narrow range?
• A central legal question may be the scope of process claims: Will the infringement analysis turn on a strict matching of the claimed process steps, or will the court consider the structural identity of Zenara's final product, irrespective of the process used to make it?